COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,802 Articles (22,527 medRxiv, 8,275 bioRxiv)

Most recent first Previous |  Page 297: Articles 2961-2970  | Next

Estimating the population effectiveness of interventions against COVID-19 in France: a modelling study
Ganser, I., Buckeridge, D. L., Heffernan, J. M., Prague, M., Thiebaut, R.
10.1101/2023.09.14.23295425 — Posted: 2023-09-14
How COVID-19 continues to affect contraception in Scotland: a retrospective analysis of Scottish prescribing data between 2016 and 2023.
Johnson-Hall, E.
10.1101/2023.09.14.23295542 — Posted: 2023-09-14
Factors associated with teenage pregnancies during the Covid-19 period in Pakwach district, Northern Uganda: a case-control study
Alunyo, J. P., Mukunya, D., Napyo, A., Matovu, J. K., Okia, D., Wanume, B., Okello, F., Tuwa, A. H., Wenani, D., Okibure, A., Omara, G., Olupot Olupot, P.
10.1101/2023.09.13.23295521 — Posted: 2023-09-14
Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic
Crits-Christoph, A., Levy, J. I., Pekar, J., Goldstein, S. A., Singh, R., Hensel, Z., Gangavarapu, K., Rogers, M. B., Moshiri, N., Garry, R. f., Holmes, E. C., Koopmans, M. P. G., Lemey, P., Popescu, S., Rambaut, A., Robertson, D. L., Suchard, M. A., Wertheim, J., Rasmussen, A. L., Andersen, K. G., Worobey, M., Debarre, F.
10.1101/2023.09.13.557637 — Posted: 2023-09-14
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19
Narasimhan, H., Cheon, I. S., Qian, W., Hu, S., Parimon, T., Zang, C., Chen, P., Sun, J.
10.1101/2023.09.13.557622 — Posted: 2023-09-14
Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern
McLaughlin, A., Montoya, V., Miller, R. L., Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, , Worobey, M., Joy, J. B.
10.1101/2023.09.12.23294140 — Posted: 2023-09-14
Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators, , Naggie, S.
10.1101/2023.09.12.23295424 — Posted: 2023-09-13
Circulation of SARS-CoV-2 and co-infection with Plasmodium falciparum in Equatorial Guinea
Lopez-Farfan, D., Ncogo, P., Oki, C., Riloha, M., Ondo, V., Cano-Jimenez, P., Martinez-Martinez, F. J., Comas, I., Irigoyen, N., Berzosa, P., Llanes, A. B., Gomez-Diaz, E.
10.1101/2023.09.12.23295464 — Posted: 2023-09-13
Changes in stillbirths and child and youth mortality in 2020 and 2021 during the Covid-19 pandemic
Acosta, E., Hug, L., Cruz-Castanheira, H., Sharrow, D., Monteiro da Silva, J. H., You, D.
10.1101/2023.09.13.23295484 — Posted: 2023-09-13
Towards mitigating health inequity via machine learning: a nationwide cohort study to develop and validate ethnicity-specific models for prediction of cardiovascular disease risk in COVID-19 patients
Allery, F., Khalid, S.
10.1101/2023.09.13.23295489 — Posted: 2023-09-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).